Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Cookies
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Have Kairos Pharma insiders bought shares recently?
No open-market purchase by an insider of Kairos Pharma was filed in the last 90 days. The latest on record was on Nov 26, 2024.
How often do Kairos Pharma insiders buy and sell shares?
Since 2024, Kairos Pharma insiders reported 3 open-market purchases and 0 sales on Forms 4 and 5, with purchases in 1 different year, most recently 2024.
Who is selling Kairos Pharma stock?
No open-market sale by an insider of Kairos Pharma (KAPA) was filed with the SEC in the last 90 days.
Do members of Congress trade KAPA?
No trade in Kairos Pharma (KAPA) was disclosed by a member of Congress in the last 12 months.
Where does this data come from?
From official filings only: SEC Forms 4, 5 and 144 for insiders, House and Senate periodic transaction reports for Congress, SEC Form 13F for funds, Form 8-K for company events and USAspending for federal contracts. Every record on OQRO links to its source. It is public data, not investment advice.
−90.9% (−$4.37) from Nov 20, 2025 to Nov 20, 2026 · adjusted daily closes
No disclosed open-market insider trades, politician trades or fund 13F changes in this period.
Adjusted close went from $4.81 on Nov 20, 2025 to $0.4359 on Nov 20, 2026 (−90.9%). Disclosed in this range: 0 insider trades, 0 pre-arranged insider sales, 0 Congress trades.
$-2$2$4$6$8$0.4359
DecJan 2026FebMarAprMayJunJulAugSepOctNov
Insider and Congress marks sit on the trade date stated in the filing; solid is a purchase, hollow a sale. A number means several trades too close to tell apart at this range: pick a shorter range or open it for the list. Congress amounts are official ranges; mark size uses the lower bound. Past moves are not a forecast.
Counts of filings OQRO holds, by the date each was filed or the award started. Every figure links to its official SEC, House, Senate or USAspending record.
Pharmaceutical Preparations company based in Los Angeles, Ca.
Last 12 months
−90.9%
S&P 500 +5.7% over the same dates
Market value
$1.91M
Close of Nov 20, 2026 × shares outstanding (per ADS where it applies)
S&P 500 +5.7% over the same dates. Prices adjusted for splits and dividends.
Short interest: 84K shares sold short (1.9% of shares outstanding), −37.5% vs the previous count, 1.0 days of normal trading to buy them back. FINRA, as of Oct 30, 2026. Short interest history
Since the trade −96.3% · S&P 500 +15.4% · to Nov 20
Kairos Pharma's VP of Research and Development paid $318 out of pocket for Kairos Pharma shares. 2 other people at Kairos Pharma bought some too, in the same month. It was the first purchase in over a year.
Since the trade −96.1% · S&P 500 +15.8% · to Nov 20
The CFO of Kairos Pharma paid $3.8K out of pocket for Kairos Pharma shares. 2 other people at Kairos Pharma bought some too, in the same month. It was the first purchase in over a year.
Since the trade −95.7% · S&P 500 +16.8% · to Nov 20
The CEO of Kairos Pharma paid $5.8K out of pocket for Kairos Pharma shares. 2 other people at Kairos Pharma bought some too, in the same month. It was the first purchase in over a year.
Prices are daily closes from Polygon.io. Company figures come from its own SEC filings. Past moves are not a forecast. OQRO reports what was filed and never tells you what to buy or sell.
Insider buying and selling since 2024
Insiders of Kairos Pharma reported 3 open-market purchases and 0 sales since 2024; purchases in 2024.
Year
Bought
Sold
2024
$9.8K3×3 trades
—
Open-market purchases (code P) and sales (code S) on Forms 4 and 5. Up to Sep 2024 from the SEC's Insider Transactions Data Sets; since Oct 2024 from each filing as it is published. A trade filed twice (an amendment) counts once. Dollar totals use the price the filer reported; lines with no price count as trades without a value.
Latest results: quarter ending Sep 30, 2026
Revenue
—
Free cash flow, last 12 months
—
Cash from operations minus capital spending
Net debt
—
Debt —, cash $3.13M, at Sep 30, 2026
Net income, last 12 months
−$6.39M
From the company's own quarterly and annual reports to the SEC. Free cash flow (cash from operations minus capital spending), net debt (debt minus cash) and 12-month totals are calculated by OQRO.
No Schedule 13D or 13G filing on KAPA over the last three years: no investor has reported crossing 5% of its stock in that time.
Source: SEC Schedules 13D and 13G, which anyone owning more than 5% of a class of stock must file. A 13D filer may seek to influence the company; a 13G filer is passive. Filings before December 2024 are free text and read from their cover page: a percent or share count that is not stated plainly is left blank. Each line links to the filing.
Risk factors in the annual report
Latest annual report filed Mar 31, 2026, compared with the one filed Apr 15, 2025. Read the filing
New risk factors in the latest annual report (2 headings)
The U.S. Congress, the Trump administration, or any new administration may make substantial changes to fiscal, tax, and other federal policies that may adversely affect our business.
The capital markets may experience periods of disruption, instability and economic uncertainty. Such market conditions may materially and adversely affect the debt and equity capital markets, which may have a negative impact on our business and operations.
No longer listed (1 heading from the year before)
We are currently operating in a period of economic uncertainty and capital markets disruption, which has been significantly impacted by geopolitical instability due to the ongoing military conflicts between Russia and Ukraine, as well as Israel and Hamas.
Legal proceedings (Item 3)
From time to time, we may become involved in material legal proceedings or be subject to claims arising in the ordinary course of our business. Regardless of outcome, such proceedings or claims can have an adverse impact on us because of defense and settlement costs, diversion of resources, and other factors, and there can be no assurances that favorable outcomes will be obtained. We are not presently party to any legal proceedings material to our operations or of which any of our property is the subject, nor are we aware of any such proceedings that are contemplated by a government authority.
Source: SEC EDGAR, Form 10-K filed Mar 31, 2026. Headings are the titles the company gives each risk; OQRO compares them with the year before by their words, so a heading that was reworded a lot shows up as both new and no longer listed. Companies list the risks they face, not forecasts.
The year in the managers' words
Every annual report has a section where the company's managers explain the year's results (Item 7, Management's discussion and analysis). In this report it runs to about 8,000 words.
From “Overview”, in the company's words
We are a clinical-stage biopharmaceutical company advancing therapeutics for cancer patients that are designed to overcome key hurdles in immune suppression and drug resistance. Our mission is to advance our portfolio of innovative therapeutics to reverse key mechanisms of therapeutic resistance and immune suppression and transform the way cancer is treated. We have leveraged molecular insights of the mechanisms of therapeutic resistance and immune suppression to develop a new class of novel drugs that are designed to target drug resistance and checkpoints of immune suppression. As of the date of this Quarterly Report, our product candidates have not been approved as safe or effective by the FDA or any other comparable foreign regulator.
What the section covers (40 headings)
Overview
Recent Developments
Equity Line of Credit Agreement (ELOC)
January 2025 PIPE Offering
2026 At the Market Offering
Components of Results of Operations
Net Sales
Operating Expenses
Research and Development Expenses
General and administrative expenses
Results of Operations
Comparison of the Years Ended December 31, 2025 and 2024
Other Income (Expenses)
Liquidity and Capital Resources
And 26 more headings in the filing.
Source: SEC EDGAR, Form 10-K filed Mar 31, 2026. The quote is the opening of the managers' discussion, cut at a sentence; the word count is estimated from its length. Not investment advice.
Off-exchange trading: 58.2% of the shares traded over the latest 4 published weeks changed hands away from the exchanges (5.9% on ATS, 52.3% with other brokers), close to its 7-week average of 59.0%. Weeks of Sep 21 to Oct 16, 2026.
Week of Aug 31ATSOther off-exchangeFull height = all shares tradedWeek of Oct 12
Largest ATS: UBS ATS (29.2%), INTELLIGENT CROSS LLC (13.0%), LEVEL ATS (9.8%), as a share of this stock's ATS volume over the same 4 weeks.
An ATS, often called a dark pool, is a private trading venue run by a broker where orders are not shown publicly before they trade. Other off-exchange trades are mostly retail orders filled by wholesale brokers. A high share is common and says nothing by itself about where the price goes. FINRA OTC Transparency data, published 2 weeks after each week for the largest stocks and 4 weeks for others; total volume from our daily price data.
OQRO Intelligence
Written by OQRO's software from the last 12 months on record · Nov 19, 2026
Insiders. In the 12 months to Nov 19, 2026, insiders of Kairos Pharma filed 0 open-market purchases (about $0, in 0 filings, by 0 people) and 0 open-market sales (about $0, in 0 filings, by 0 people). One Form 4 can list many transactions. In the 12 months before that, they filed 3 open-market purchases (about $9.8K, in 3 filings) and 0 open-market sales (about $0, in 0 filings). (Kairos Pharma on OQRO)
Contracts, lobbying and filings. FINRA short interest for KAPA on the settlement date of Oct 30, 2026 was 84,066 shares (-37.51% on the previous report), about 1 days of average volume.
Company reports, price and press. Kairos Pharma filed a Form 8-K on Nov 3, 2026 (Items 1.01, 8.01) that OQRO classes as: signed an important agreement, and reported other company news. Kairos Pharma filed a Form 8-K on Aug 21, 2026 (Items 3.03, 5.03, 7.01) that OQRO classes as: changed the rights of its shareholders, and changed its bylaws, charter or fiscal year (and 1 more item).
Things to keep in mind. These are counts of the filings OQRO holds, in the days they were filed; a busy or quiet month does not say why. A Form 4 reports a transaction; it does not say why it was made, and some follow trading windows or pre-arranged plans. Congress reports give only amount ranges and arrive after the trade. An 8-K item says what the company reported, not what it means for the share price.
Facts used for this text
Every number, name, date and link in the text above comes from this list; software checks that before the text is stored. This text was assembled directly from the facts, without a language model.
Insiders
In the 12 months to Nov 19, 2026, insiders of Kairos Pharma filed 0 open-market purchases (about $0, in 0 filings, by 0 people) and 0 open-market sales (about $0, in 0 filings, by 0 people). One Form 4 can list many transactions.
In the 12 months before that, they filed 3 open-market purchases (about $9.8K, in 3 filings) and 0 open-market sales (about $0, in 0 filings).
Contracts, lobbying and filings
FINRA short interest for KAPA on the settlement date of Oct 30, 2026 was 84,066 shares (-37.51% on the previous report), about 1 days of average volume.
Company reports, price and press
Kairos Pharma filed a Form 8-K on Nov 3, 2026 (Items 1.01, 8.01) that OQRO classes as: signed an important agreement, and reported other company news.
Kairos Pharma filed a Form 8-K on Aug 21, 2026 (Items 3.03, 5.03, 7.01) that OQRO classes as: changed the rights of its shareholders, and changed its bylaws, charter or fiscal year (and 1 more item).
Kairos Pharma filed a Form 8-K on Jul 22, 2026 (Items 1.01, 8.01) that OQRO classes as: signed an important agreement, and reported other company news.
Press coverage listed by Finnhub: "Kairos Pharma Recognized by Biotech Breakthrough Awards in Oncology" (Yahoo, Nov 5, 2026).
Press coverage listed by Finnhub: "Kairos Pharma Presents at United Scientific Group’s 11th International Conference on Cancer Research & Drug Development" (Yahoo, Nov 3, 2026).
Press coverage listed by Finnhub: "CEO.CA's Inside the Boardroom: Major U.S. Cancer Centers Are Testing This New Drug: Kairos Pharma" (Yahoo, Oct 22, 2026).
KAPA closed at $0.4403 on Nov 18, 2026, the last session on or before the end of the period.
From Oct 19, 2026 to Nov 18, 2026, the close moved from $0.5701 to $0.4403, a change of −22.8%.
Things to keep in mind
These are counts of the filings OQRO holds, in the days they were filed; a busy or quiet month does not say why.
A Form 4 reports a transaction; it does not say why it was made, and some follow trading windows or pre-arranged plans. Congress reports give only amount ranges and arrive after the trade.
An 8-K item says what the company reported, not what it means for the share price.
Headlines are listed as published by the outlets; OQRO has not checked them and does not summarise articles.
Share price moves are listed as context only; the filing does not explain them and other news can move a price.
This describes public filings. It is not investment advice.